MDXG Earnings Prediction
The chart below shows how MDXG performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MDXG sees a +0.30% change in stock price 10 days leading up to the earnings, and a +10.80% change 10 days following the report. On the earnings day itself, the stock moves by -0.29%. This data can give you a slight idea of what to expect for the next quarter's release.
MDXG Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
92.91M
7.00%
10.53%
Gross Margin
81.59%
-2.68%
0.06%
Operating Margin
12.05%
-56.31%
-16.38%
Net Margin
8.01%
-88.90%
-14.51%
EPS
0.05
-78.26%
0.00%
No Data Available
MDXG Earnings Analysis
MiMedx Group Inc Corporation (MDXG.O) Earnings Conference Call
Positive
Revenue Growth Performance: Full year revenue grew by 9%, indicating strong overall performance.
Q4 Net Sales Growth: Q4 net sales grew year-over-year by approximately 7% to $93 million, showcasing solid growth.
High Gross Profit Margin: Gross profit margin was 82% in the quarter, reflecting efficient cost management.
Strong Profitability Indicator: Adjusted EBITDA was $20 million or 21% of sales in Q4, demonstrating strong profitability.
Cash Flow Management Success: The company ended the year with $104 million in cash, an increase of $16 million during the quarter, indicating strong cash flow management.
Xenograft Product Launch: The market release of HELIOGEN, the first xenograft product, is gaining traction, which could enhance future sales.
Product Growth Surge: EPIEFFECT and AMNIOEFFECT products are showing strong growth, with AMNIOEFFECT growing at close to 20% year-over-year in the surgical market.
Japan Sales Surge: Sales in Japan nearly tripled in 2024, indicating successful international expansion.
Medicare Reimbursement Opportunities: The company is well-positioned to capitalize on upcoming Medicare reimbursement changes, which could enhance market share.
Customer Portal Adoption: The introduction of MiMedx Connect, a customer portal, has seen excellent adoption, improving customer relationships and operational efficiency.
Negative
Medicare Reimbursement Challenges: Challenges due to Medicare reimbursement issues affecting sales performance.
Sales Force Turnover Impact: Above average sales force turnover in select markets impacting growth.
Net Income Decline: GAAP net income decreased significantly from $53 million in Q4 2023 to $7 million in Q4 2024, primarily due to a one-time tax benefit in the prior year.
EBITDA Margin Decline: Adjusted EBITDA margin decreased from 24% in Q4 2023 to 21% in Q4 2024, indicating reduced profitability.
Gross Margin Decline: Gross margin declined from 84% in Q4 2023 to 82% in Q4 2024, reflecting increased costs.
R&D Expense Increase: R&D expenses increased by 38% compared to the prior year, indicating higher investment but also potential strain on profitability.
Market Confusion Anticipation: The company anticipates potential confusion in the market due to changes in ordering patterns and practices as a result of the upcoming LCDs implementation.
MDXG FAQs
How does MDXG typically perform around its earnings report dates?
Is MiMedx Group Inc (MDXG) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
MDXG Earning Call Sentiment
MiMedx Group, Inc. (MDXG) Q4 2024 Earnings Call Transcript
MDXG.O
0.38%Positive
The earnings call presented mixed signals. While financial performance showed growth in net sales and free cash flow, challenges like Medicare reimbursement issues and sales force turnover pose risks. The Q&A revealed uncertainty about LCD impacts and limited HELIOGEN contributions. Despite raised revenue guidance, declining margins and cautious management responses temper expectations. Without market cap data, the reaction remains neutral, balancing positive guidance against operational challenges.
